NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19 | NIH: National Institute of Allergy and Infectious Diseases

Thursday, May 14, 2020 NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19 A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19. The study will enroll approximately 2,000 adults in the United States with mild to moderate COVID-19.  Participants will be randomly assigned to receive short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.